A recent study also demonstrates that pharmacologic androgen receptor antagonism with enzalutamide inhibits hepatocellular carcinogenesis in a diethylnitrosamine- (DEN-) induced HCC mouse model. Here, AR is linked to hepatocellular carcinoma.